ES-SCLC Patients with PD-L1<sup>+</sup> CTCs and High Percentages of CD8<sup>+</sup>PD-1<sup>+</sup>T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

ES-SCLC Patients with PD-L1<sup>+</sup> CTCs and High Percentages of CD8<sup>+</sup>PD-1<sup>+</sup>T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

SCLC is an aggressive cancer type with high metastatic potential and bad prognosis. CTCs are a valuable source of tumor cells in blood circulation and are among the major contributors to metastasis. In this study we evaluated the number of CTCs that express PD-L1 in treatment-naïve ES-SCLC patients...

Full description

Bibliographic Details
Main Authors: Anastasia Xagara, Argyro Roumeliotou, Alexandros Kokkalis, Konstantinos Tsapakidis, Dimitris Papakonstantinou, Vassilis Papadopoulos, Ioannis Samaras, Evagelia Chantzara, Galatea Kallergi, Athanasios Kotsakis
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Biomedicines
Subjects:
ES-SCLC
CTCs
PD-L1<sup>+</sup>CTCs
CD8<sup>+</sup> T-cells
PD-1<sup>+</sup> T-cells
ICI therapy
Online Access:https://www.mdpi.com/2227-9059/12/1/146

Internet

https://www.mdpi.com/2227-9059/12/1/146

Similar Items